Two years later, a new fully human IgG1 mAb targeting PD-L1 (durvalumab) received the FDA approval to treat patients with unresectable advanced NSCLC, who were previously treated with chemoradiation [47]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.